Medtronic Investors Sue Over $3 Billion Inflated Stock Buyback

Medtronic investors accused the medical device maker’s directors of making misleading statements about their marketing of the company’s bone growth-stimulating device for off-label uses, causing the company to repurchase more than $2.8 billion of its own stock at inflated prices.
Law360